Market Summary
USD11.73-0.38
Delayed-3.14%
SKIN Stock Price
SKIN RSI Chart
SKIN Valuation
SKIN Price/Sales (Trailing)
SKIN Profitability
SKIN Fundamentals
SKIN Revenue
SKIN Earnings
Price Action
52 Week Range
8.2518.68
(Low)(High)
Last 7 days
2.9%
Last 30 days
4.1%
Last 90 days
35.9%
Trailing 12 Months
-28.6%
SKIN Financial Health
SKIN Investor Care
Peers (Alternatives to SKINOVATION PHARMACEUTICAL)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AAPL | 2.5T | 387.5B | 7.89% | -9.00% | 26.35 | 6.47 | 2.44% | -5.35% |
MSFT | 2.1T | 204.1B | 10.90% | -8.33% | 30.51 | 10.08 | 10.38% | -5.25% |
GOOG | 1.3T | 282.8B | 15.34% | -27.18% | 22.08 | 4.68 | 9.78% | -21.12% |
AMZN | 1.0T | 514.0B | 4.86% | -40.50% | -368.89 | 1.95 | 9.40% | -108.16% |
| MID-CAP | ||||||||
NYMT | 3.4B | 258.4M | -7.02% | -24.34% | -11.46 | 13.24 | 24.91% | -254.56% |
JBLU | 2.2B | 9.2B | -16.32% | -53.16% | -6.16 | 0.24 | 51.67% | -98.90% |
| SMALL-CAP | ||||||||
PLAY | 1.7B | 1.7B | -10.56% | -16.75% | 14.09 | 1 | 61.79% | 371.82% |
TLRY | 1.6B | 602.5M | -7.75% | -62.41% | -2.78 | 2.67 | 18.18% | -18.59% |
BYND | 1.0B | 418.9M | -15.70% | -67.27% | -2.77 | 2.42 | -9.85% | -101.06% |
MFA | 986.5M | 482.4M | -10.53% | -34.93% | -4.26 | 2.04 | 33.15% | -170.42% |
CGC | 913.9M | 478.9M | -19.31% | -78.37% | -0.29 | 1.91 | -31.50% | -634.70% |
NKLA | 774.5M | 50.8M | -31.98% | -85.06% | -0.99 | 15.24 | 1229.98% | -13.59% |
GPRO | 754.2M | 1.1B | -5.84% | -42.17% | 26.14 | 0.69 | -5.82% | -92.23% |
INO | 227.8M | 10.3M | -28.62% | -74.83% | -0.81 | 22.2 | 478.23% | 7.85% |
Financials for SKINOVATION PHARMACEUTICAL
| Income Statement (Last 12 Months) | ||||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 |
| Revenue | 10.7% | 287,959,000 | 260,086,000 | 220,077,000 | 186,490,000 | 134,098,000 |
| Gross Profit | 11.1% | 202,024,000 | 181,827,000 | 148,103,000 | 122,985,000 | 80,010,000 |
| Operating Expenses | 1.5% | 14,040 | 13,830 | 13,700 | - | - |
| S&GA Expenses | 1.5% | 14,040 | 13,830 | 13,700 | - | - |
| R&D Expenses | 9.5% | 8,973,000 | 8,195,000 | 7,180,000 | 5,877,000 | 3,486,000 |
| EBITDA | - | -348,864,215 | - | - | - | - |
| EBITDA Margin | - | -1.21 | - | - | - | - |
| Earnings Before Taxes | 10.3% | -338,648,000 | -377,350,000 | -371,643,000 | -158,176,000 | -30,377,000 |
| EBT Margin | - | -1.18 | - | - | - | - |
| Interest Expenses | 1.2% | 18,845 | 18,620 | 18,430 | - | - |
| Net Income | -1.3% | -32,885 | -32,450 | -32,130 | - | - |
| Net Income Margin | - | -1.29 | - | - | - | - |
| Free Cahsflow | -32.1% | -14,804,940 | -11,207,830 | - | - | - |
| Balance Sheet | (In Thousands) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q3 | 2021Q4 | 2021Q2 | 2021Q1 | 2020Q4 |
| Assets | 563.1% | 1.00 | 222* | 2.00 | 2.00 | 4.00 |
| Current Assets | 563.1% | 1.00 | 222* | 2.00 | 2.00 | 4.00 |
| Cash Equivalents | 563.1% | 1.00 | 222* | 2.00 | 2.00 | 4.00 |
| Inventory | 48.4% | 35,261 | 23,762 | 23,202 | - | - |
| Net PPE | 10.0% | 10,113 | 9,191 | - | - | - |
| Goodwill | 20.0% | 123,694 | 103,100 | 98,535 | 98,531 | - |
| Liabilities | 7.2% | 405 | 378 | 364 | 357 | 349 |
| Current Liabilities | 7.2% | 405 | 378 | 364 | 357 | 349 |
| Shareholder's Equity | 1781.1% | 302,297 | 16,070 | - | - | - |
| Retained Earnings | -6.4% | -429 | -403 | -388 | -381 | -371 |
| Additional Paid-In Capital | 0% | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 |
| Shares Outstanding | 0% | 708 | 708 | 708 | 708 | 708 |
| Float | -100.0% | - | 557,520 | - | - | - |
| Cashflow (Last 12 Months) | (In Thousands) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
| Cashflow From Operations | -19.4% | -8.08 | -6.77 | -10.24 | -6.83 | -7.70 |
| Share Based Compensation | 56.5% | 19,433 | 12,418 | 8,661 | - | - |
| Cashflow From Financing | 80.0% | 9.00 | 5.00 | 7.00 | 4.00 | 0.00 |
| Buy Backs | - | 0.00 | - | - | - | - |
Risks for SKIN
What is the probability of a big loss on SKIN?
70%
Probability that SKINOVATION PHARMACEUTICAL stock will be more than 20% underwater in next one year
64%
Probability that SKINOVATION PHARMACEUTICAL stock will be more than 30% underwater in next one year.
64%
Probability that SKINOVATION PHARMACEUTICAL stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does SKIN drawdown profile look like?
Y-axis is the maximum loss one would have experienced if SKINOVATION PHARMACEUTICAL was unfortunately bought at previous high price.
Drawdowns
Returns for SKIN
Cumulative Returns on SKIN
Which funds bought or sold SKIN recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-23 | MetLife Investment Management, LLC | unchanged | - | -144,286 | 488,106 | -% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -87.86 | -16,014,000 | 1,656,030 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -20.13 | -180,000 | 288,000 | -% |
2023-02-28 | Voya Investment Management LLC | reduced | -46.12 | -46,548,200 | 610,755 | -% |
2023-02-27 | Parallax Volatility Advisers, L.P. | added | 31.17 | -22.00 | 22,978 | -% |
2023-02-22 | Kovack Advisors, Inc. | added | 8.63 | -70,270 | 366,730 | 0.05% |
2023-02-15 | Metropolitan Life Insurance Co/NY | added | 10.83 | -9,532 | 58,468 | -% |
2023-02-15 | BRIDGER MANAGEMENT, LLC | sold off | -100 | -5,265,000 | - | -% |
2023-02-15 | ALLIANCEBERNSTEIN L.P. | unchanged | - | -846,050 | 2,861,950 | -% |
2023-02-15 | Steward Partners Investment Advisory, LLC | added | 21.21 | -720 | 7,280 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
SKINOVATION PHARMACEUTICAL News
Schedule 13G FIlings of SKINOVATION PHARMACEUTICAL
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2022 | luxor capital group, lp | 1% | 143,628 | SC 13G/A | |
| Feb 11, 2022 | baupost group llc/ma | 0% | 0 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 6.41% | 9,599,134 | SC 13G |
SKIN Fair Value
SKINOVATION PHARMACEUTICAL fair value in different scenarios
The table shows the Fair Value estimates for SKINOVATION PHARMACEUTICAL for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | 31.72 170.42% | 65.54 458.74% | 333.84 2746.04% | 747.04 6268.63% | 1171.41 9886.45% |
| Current Inflation | 29.47 151.24% | 60.19 413.13% | 294.06 2406.91% | 647.84 5422.93% | 1009.22 8503.75% |
| Very High Inflation | 26.63 127.02% | 53.59 356.86% | 247.08 2006.39% | 532.59 4440.41% | 822.11 6908.61% |
Historical SKINOVATION PHARMACEUTICAL Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
SKIN Income Statement
2022-09-30Condensed Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
| Income Statement [Abstract] | ||||
| REVENUES | ||||
| OPERATING EXPENSES | ||||
| General and administrative | 2,760 | 2,800 | 11,250 | 11,000 |
| TOTAL EXPENSES | 2,760 | 2,800 | 11,250 | 11,000 |
| Loss from operations | (2,760) | (2,800) | (11,250) | (11,000) |
| OTHER INCOME (EXPENSE) | ||||
| Interest expense | (4,969) | (4,680) | (14,704) | (13,940) |
| Total other income (expense) | (4,969) | (4,680) | (14,704) | (13,940) |
| LOSS BEFORE INCOME TAXES | (7,729) | (7,480) | (25,954) | (24,940) |
| INCOME TAX EXPENSE | ||||
| NET LOSS | $ (7,729) | $ (7,480) | $ (25,954) | $ (24,940) |
| Basic and diluted net loss per share | $ (0.01) | $ (0.01) | $ (0.04) | $ (0.04) |
| Basic and diluted weighted average shares outstanding | 708,000 | 708,000 | 708,000 | 708,000 |
SKIN Balance Sheet
2022-09-30Condensed Balance Sheets (Unaudited) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current Assets | ||
| Cash | $ 1,472 | $ 222 |
| Total Current Assets | 1,472 | 222 |
| Total Assets | 1,472 | 222 |
| Current Liabilities | ||
| Accounts payable | 10,500 | 7,000 |
| Notes payable | 249,021 | 240,021 |
| Accrued interest | 145,497 | 130,793 |
| Total Current Liabilities | 405,018 | 377,814 |
| Total Liabilities | 405,018 | 377,814 |
| Stockholders' Deficit | ||
| Preferred stock, $.001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding | ||
| Common stock, $.001 par value; 50,000,000 shares authorized; 708,000 shares issued and outstanding | 708 | 708 |
| Additional paid-in capital | 25,148 | 25,148 |
| Accumulated deficit | (429,402) | (403,448) |
| Total Stockholders' Deficit | (403,546) | (377,592) |
| Total Liabilities and Stockholders' Deficit | $ 1,472 | $ 222 |